secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2025-10-17T23:59:59+00:00
Accession:  0001213900-25-099752
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX: FDA clinical hold update – narrow nebulizer queries, no drug concerns; EU enrollment ahead
--------------------------------------------------------------------------------

- FDA provided additional narrow questions on third-party nebulizer; no concerns about BX004 drug product.
- BiomX believes it has fully addressed the FDA's queries.
- European portion of Phase 2b study continues enrollment ahead of plan; topline results on track for Q1 2026.
- FDA recognized unmet medical need for chronic Pseudomonas aeruginosa infection in CF and outlined potential Phase 3 pathways.
- BiomX plans to incorporate FDA feedback into development; expects End-of-Phase 2 meeting after trial completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025099752/0001213900-25-099752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390025099752/ea0261617-8k_biomx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-099752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer